The Netherlands Cancer Institute: Melanoma trials

The registry lists 14 Melanoma studies with The Netherlands Cancer Institute as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 9Phase 3 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Contrast-enhanced Ultrasound for Sentinel Node DetectionRecruitingNCT07310758Phase 2/3
• Intradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaRecruitingNCT06240143Phase 1/2
• 'Cancer Patients Better Life Experience'RecruitingNCT05827289Not applicable
• FMT to Convert Response to ImmunotherapyRecruitingNCT05251389Phase 1/2
• Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node BiopsyCompletedNCT06666634Not applicable
• Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III MelanomaActive, not recruitingNCT04949113Phase 3
• Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable DiseaseCompletedNCT04330430Phase 2
• Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaCompletedNCT04133948Phase 1/2
• Optimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabActive, not recruitingNCT02977052Phase 2
• HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced MelanomaCompletedNCT02836548Phase 1/2
• Study With T-cel Receptor Gene Therapy in Metastatic MelanomaStatus unknownNCT02654821Phase 1/2
• Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma PatientsStatus unknownNCT02625337Phase 2
• Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma PatientsActive, not recruitingNCT02437279Phase 1
• Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02278887Phase 3